Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
19 nov. 2019 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
21 juil. 2019 06h03 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 18/2019Company Registration No. 32266355 ...
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
07 juin 2019 00h56 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
30 janv. 2019 01h14 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)
28 sept. 2018 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme to Present at 25th NPUK Annual Family Conference 2018
20 sept. 2018 09h19 HE
|
ORPHAZYME A/S
Orphazyme A/SInvestor news No....
Sucampo to Host 2017 R&D Day on November 16 in New York
09 nov. 2017 17h48 HE
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its 2017 R&D Day...
Sucampo Reports Second Quarter 2017 Financial Results
02 août 2017 06h30 HE
|
Sucampo Pharmaceuticals Inc
Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse...
Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
13 juin 2017 16h30 HE
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., June 13, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the U.S. Patent and Trademark Office...
Sucampo Acquires Vtesse Inc.
03 avr. 2017 06h30 HE
|
Sucampo Pharmaceuticals Inc
Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1) Increases Company Focus on Specialized Diseases with High Unmet Need ...